ObjectiveTo analyze the clinical efficacy of cetuximab combined with fluorouracil/calcium folinate + oxaliplatin (mFOLFOX6) in the treatment of patients with advanced colorectal cancer. MethodsA total of 62 patients with advanced colorectal cancer were selected as the research objects and randomly divided into the observation group and the control group, with 31 cases in each group. Patients in the control group were treated with mFOLFOX6 regimen, based on which patients in the observation group were treated with cetuximab additionally. The serum tumor markers levels, Karnofsky performance status(KPS) scale score, clinical efficacy and side effects were compared between the two groups. ResultsBefore treatment, there was no statistically significant difference in serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels between the two groups (all P＞0.05). After 4 courses of treatment, the levels of serum carcinoembryonic antigen and carbohydrate antigen 19-9 in the two groups decreased, and the levels of the aforementioned indicators in the observation group were lower than those in the control group (all P＜0.05). Before treatment, there was no statistically significant difference in the KPS scale score between the two groups (P＞0.05). After 4 courses of treatment, the scores of KPS scale of both groups increased, and the observation group was higher than the control group (P＜0.05). After 4 courses of treatment, the objective response rate and disease control rate in the observation group were higher than those in the control group (all P＜0.05). During treatment, the incidence of acneiform rash in the observation group was higher than that in the control group (P＜0.05). ConclusionCetuximab combined with mFOLFOX6 has a significant clinical efficacy in the treatment of patients with advanced colorectal cancer, but the incidence of acneiform rash in patients is quite high.

无